USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: AZEVAN PHARMACEUTICALS, INC.
City: BETHLEHEM
State: PA
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (610) 758-3620

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $449,195.00 2
SBIR Phase II $1,794,075.00 2
STTR Phase I $241,071.00 3
STTR Phase II $498,684.00 1

Award List:

N/A

Award Year / Program / Phase: 2000 / STTR / Phase I
Agency: HHS
Research Institution: Lehigh University
Principal Investigator: Neal Simon, Principal Investigator
Award Amount: $100,000.00
RI Contact: N/A

A NEW DRUG FOR DEPRESSION

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Neal G. Simon
Award Amount: $100,000.00
Abstract:
Long Term Goals: Serenix Pharmaceuticals (SP) will develop drugs for the treatment of CNS disorders. Strategy: SP acquired a series of vasopressin receptor antagonists from Eli Lilly and Company and has refined these molecules through manipulations of various structural zones. A subset of these… More

A Potential New Drug for Depression

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Eve M. Damiano
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): A Potential New Drug for Depression, an active SBIR Phase IIa award. The requested funds will allow additional characterization studies of three newly discovered mixed vasopressin 1a/1b antagonists, studies that were not part of the original application. These… More

New Drugs for Stress-related Affective Illness

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael Brownstein
Award Amount: $349,195.00
Abstract:
DESCRIPTION (provided by applicant): Vasopressin (AVP) antagonists represent a novel therapeutic class for the treatment of depression. The potential utility of these compounds has emerged from observations in depressed individuals, findings in animal mode ls, and an understanding of changes in… More

Screening New Therapeutics for the Treatment of Post Traumatic Stress Disorder

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency: HHS
Research Institution: NORTHEASTERN UNIVERSITY
Principal Investigator: Neal G. Simon – 610-758-3620
Award Amount: $141,071.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Project Summary/Abstract Post-traumatic Stress Disorder (PTSD) is recognized by the NIMH, the Department of Defense, and the Veterans' Administration as a major medical issue. Recent studies indicate that the incidence of PTSD among Iraq and Afghanistan… More

New Drugs for Stress-related Affective Illness

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Michael Brownstein – 610-419-1057
Award Amount: $1,794,075.00
Abstract:
DESCRIPTION (provided by applicant): Vasopressin (AVP) antagonists represent a novel therapeutic class for the treatment of depression. The potential utility of these compounds has emerged from observations in depressed individuals, findings in animal models, and an understanding of changes in… More